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ABSTRACT
Introduction: To determine whether there is a
statistically significant difference in the
decrease in intraocular pressure (IOP) after
selective laser trabeculoplasty (SLT) between
patients receiving a 5–7 days co-administration
of loteprednol versus no loteprednol over the
course of 1 year.
Methods: We conducted a retrospective chart
review to evaluate use of loteprednol in patients
aged 30–85 years undergoing SLT for open-angle
glaucoma at our center over a 3-year period.
Results: Three hundred and eighteen eyes from
313 patients who underwent a 360 SLT
treatment between January 2008 and August
2011 were included in the analysis. Patients
who received loteprednol showed a mean
reduction of 2.5 (±SE 0.3) mmHg or 11.8%
(±1.5%) in IOP versus a mean reduction of 3.2
(±0.6) mmHg or 14.9% (±2.5%) in those not
treated with loteprednol. This difference
showed a trend toward lower IOP without
loteprednol, but this was not statistically
significant (p = 0.29).
Conclusion: Postoperative use of loteprednol
does not appear to significantly affect IOP in
patients undergoing SLT. A randomized double-
blinded study in a larger group of patients
would be required to clarify this issue. Until
such information is available, we recommend
that individual clinical judgment be used
regarding whether to use topical steroids in
patients undergoing SLT.
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INTRODUCTION
Trabeculoplasty, the common term used for the
treatment of the trabecular meshwork with laser
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to lower intraocular pressure (IOP), has a long
history, beginning with Krashnov’s use of a
ruby laser to treat glaucoma in 1972 [1]. Other
lasers were tried, the most common procedure
being the argon laser trabeculoplasty (ALT) used
by Hager [2]. Today, the commercially available
laser is the Q-switched, double-frequency
neodymium:yttrium–aluminum–garnet
(Nd:YAG) laser with a wavelength of 532 nm.
This was first described by Latina in 1995 and
the procedure was named selective laser
trabeculoplasty (SLT) [3, 4]. This laser
selectively targets pigmented trabecular
meshwork cells and treatment can be repeated
with no thermal damage [4, 5].
Two main theories have been suggested for
ALT and have been well described [6–9]. These
include the mechanical theory by Wise and
Witter [6] and the cellular and biological theory
by Van Buskirk [7]. These theories are based on
findings from studies using electron microscopy
and histopathology. Originally, it was thought
that laser treatment caused a mechanical
trabeculopuncture, allowing the aqueous to
flow more readily through the trabecular
meshwork [10–12]. In support of the
mechanical theory, there has been shown to
be a disruption of the trabecular beams of the
uveal and corneoscleral trabecular meshwork
with surrounding coagulative damage. Weeks
later, fibrosis was shown to develop [10–12].
Further studies have shown shrinkage of the
trabecular ring, separation of trabecular sheets,
opening of aqueous channels, and an opening
traction on Schlemm’s Canal [10–12]. The
cellular and biological theories are based on
studies that have shown an increase in a
macrophage-like phagocytic activity of
trabecular meshwork cells, increased turnover
and synthesis of glycosaminoglycans, increased
cell division of trabecular meshwork cells and
an induced inflammatory response. These
biologic and cellular changes generally take
4–6 weeks to develop [13]. Conversely, eyes
that have undergone SLT show no alteration
of the collagen structure of the trabecular beams
and no evidence of coagulative damage. There
was, however, a disruption of trabecular
endothelial cells with subsequent cellular
division and increased phagocytic activity [5].
As a result of the biologic and cellular theory,
clinical studies have been performed primarily
on ALT to determine the role of inflammation
and its inhibition. The Fluorometholone-Laser
Study Group conducted a prospective,
randomized, study on the effects of
corticosteroid treatment on ALT [14]. This
short-term study was later extended to a
follow-up period of 4.6 ± 3.4 years [14, 15].
Both the short- and long-term studies found
no statistically significant difference in IOP with
administration of fluorometholone between the
two groups (p = 0.51).
There is a paucity of published data on the
effect of corticosteroid administration and
efficacy of SLT, which has a presumed biologic
and cellular mechanism only [16, 17]. Realini
conducted a randomized, observer-masked study
of 25 participants who received bilateral 360 SLT
and prednisolone acetate four times per day for
1 week in one eye only [15, 16]. This study
showed no statistically significant difference in
IOP decrease at 1 week, 3 weeks, and 3 months.
There was also no statistically significant
difference in IOP decrease over the course of
1 year for concurrent ketorolac 1% (n = 14)
versus prednisolone acetate 1% (n = 60)
treatment in a subset of patients participating
in a multicenter, prospective, nonrandomized
study that evaluated SLT as an initial and
adjunctive treatment versus latanoprost [17].
There have thus far been no published
studies of SLT with a follow-up greater than
3 months comparing corticosteroid versus no
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corticosteroid. In addition, all previous studies
had small sample sizes. Thus, we conducted a
retrospective chart review to evaluate use of
loteprednol in a large series of patients treated
with SLT at our center.
MATERIALS AND METHODS
This study was a single-center, retrospective
chart review of patients from Sabates Eye
Centers, a multispecialty ophthalmology
practice based on the Kansas City, MO, area.
We searched the Next Gen (NextGen
Healthcare Information Systems, Inc.
Horsham, PA, USA) database at Sabates Eye
Centers (Kansas City, MO, USA) for patients
aged 30–85 years with the procedure code of
SLT (66984), between January 1, 2008 and
August 31, 2011.
The patients were initially listed by medical
record number but were subsequently assigned
research identifiers to prevent patient
identification. We then limited patients
according to the following inclusion and
exclusion criteria. Patients with a diagnosis of
open-angle glaucoma (diagnosis codes of
primary open-angle glaucoma, normal tension
glaucoma, pigmentary glaucoma, or
pseudoexfoliation glaucoma) were eligible for
inclusion. Those with angle-closure,
inflammatory, or secondary type of glaucoma
were excluded. Also excluded were patients who
received a topical corticosteroid of any type for
another indication 1 month prior to SLT, or
3 months subsequent to SLT, and those with
previous SLT in the same eye, cataract extraction
less than 6 months prior to SLT, or any previous
intraocular surgery other than cataract surgery.
We documented IOP measurements and the
number of glaucoma medications at baseline,
which was defined as the most recent IOP
measurement prior to SLT. IOP measurements
and the number of glaucoma medications at
1 month ± 2 weeks, 4 months ± 2 months, and
at 1 year ± 3 months were analyzed to follow
progression over the course of 1 year.
Combination medications, i.e., COMBIGAN
(brimonidine tartrate/timolol maleate
ophthalmic solution 0.2%/0.5% Allergan, Inc.,
Irvine, CA 92612, USA), were considered to be
two medications. IOP was measured with
Goldmann tonometry. The presence of
anterior chamber reaction was not collected.
Statistical analysis was performed with
support from the Department of Biomedical
and Health Informatics at the University of
Missouri-Kansas City (Kansas City, MO, USA).
Bivariate comparisons were conducted on the
age of the patient, number of medications at
baseline and 1 year, and IOP at baseline and at
1 year, at which time the IOP was assumed to
have stabilized. p values were determined by
Chi-square comparison for the categorical
variable (sex) and non-paired t tests for
continuous variables. p values \0.05 were
regarded as statistically significant. To control
for the retrospective nature of this study and
improve baseline balance between the group
receiving and not receiving loteprednol,
respectively, nearest-neighbor matching, as
implemented by the R statistical computing
(version 3.0.1) package MATCHIT (version 2.4-21),
was also utilized [18–20]. Each eye not receiving
corticosteroid was nonexclusively matched to
the three most similar eyes receiving
corticosteroid. Similarity was determined based
on all available baseline characteristics
including IOP, age, sex, and number of
medications. This statistical method has been
shown to improve inferences when treatment
(steroid versus no steroid) was not assigned in a
randomized fashion [19].
Analyses were conducted to determine
whether absolute and percentage change in
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IOP measurements from baseline to 1 year (i.e.,
9–15 months following surgery) differed
between patients receiving and those not
receiving loteprednol. To test this difference, a
repeated measures analysis of variance
(ANOVA) was performed on the unmatched
data. Additional analyses used the nearest-
neighbor matching process. Mean treatment
effects on the baseline to 1 year change in IOP
were computed using the R statistical
computing package Zelig (version 3.5.4) after
controlling for baseline IOP, the baseline
number of medications, and the type of
glaucoma [18, 21, 22] Unless otherwise noted,
results, figures, and percentages are reported for
the raw unmatched data.
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
Retrospective chart reviews yielded data from
724 eyes in 642 patients. 318 eyes from 313
patients were eligible for inclusion in the
analysis: 207 who received loteprednol for
5–7 days at the time of surgery, and 111 who
did not. 228 of these patients were seen at or
around 1 year following SLT. Bivariate and
descriptive comparisons of the two groups of
patients are shown in Tables 1 and 2. In these
bivariate analyses, the only difference between
patients receiving and those not receiving
loteprednol was IOP at baseline, which was
significantly higher in those not receiving
Table 1 Bivariate comparisons of continuous variables in patients receiving loteprednol versus those not receiving
loteprednol
Variable Total (n5 313) Loteprednol (n 5 207) No loteprednol (n 5 111) p
Mean SE Mean SE Mean SE
Age (years) 70.5 0.60 70.5 0.73 70.5 1.04 0.994
No. of medications at baseline 1.5 0.07 1.5 0.09 1.5 0.12 0.999
No. of medications at 1 year 1.6 0.07 1.6 0.09 1.5 0.11 0.771
IOP at baseline (mmHg) 17.6 0.25 16.9 0.30 18.9 0.43 \0.001*
IOP at 1 year (mmHg) 14.8 0.22 14.6 0.25 15.3 0.44 0.186
Absolute IOP decrease (mmHg) 2.67 0.251 2.46 0.28 3.23 0.55 0.175
Percentage IOP decrease 13% 1.3% 12% 1.5% 15% 2.5% 0.288
IOP intraocular pressure
* Statistically signiﬁcant at a = 0.05
Table 2 Chi-squared comparison of gender distribution in patients receiving loteprednol versus those not receiving
loteprednol
Variable Total (n5 313) Loteprednol (n5 207) No loteprednol (n5 111) p
N % n % n %
Sex (female) 185 58.4 120 58.3 65 58.6 0.958
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loteprednol. However, following nearest-
neighbor matching, baseline IOP was no longer
significantly different between the treatment
groups (p = 0.82).
The test of the interaction effect (steroid x
time) was not statistically significant (p = 0.18),
as seen in Fig. 1. 195 patients (228 eyes) had IOP
measurements available approximately 1 year
following SLT. The tests of main effects showed
that there was a statistically significant decline
in IOP from baseline to 1 year (p\0.001), and
that in the raw data the loteprednol group had
lower mean IOP at both time periods
(p = 0.038). Absolute IOP and absolute IOP
decrease can be seen in Figs. 1 and 2,
respectively. After nearest-neighbor matching,
the loteprednol group no longer had a
significantly different IOP from the no
loteprednol group at 1 year (p = 0.55).
Loteprednol had no statistically significant
effect on the change in IOP at 1 month (235
eyes, 95% CI -1.7 to 0.7 mmHg), 4 months
(244 eyes, 95% CI -0.9 to 0.2 mmHg), or 1 year
(228 eyes, 95% CI -0.5 to 0.9 mmHg).
We ran additional analyses to test whether
the two groups differed in percentage change in
IOP between baseline and 1 year. Patients who
received loteprednol showed a mean reduction
of 12% (±SE 1.5%) in IOP, while patients
without loteprednol showed a mean reduction
Fig. 1 Absolute intraocular pressure (IOP) (mean ± stan-
dard error) over the course of 1 year in patients receiving
loteprednol versus those not receiving loteprednol
Fig. 2 Absolute decrease versus baseline (mean ± standard
error) in intraocular pressure (IOP) over the course of
1 year in patients receiving loteprednol at time of surgery
versus those not receiving loteprednol (p = 0.18)
Fig. 3 Percentage decrease (mean ± standard error) in
intraocular pressure (IOP) over the course of 1 year in
patients receiving a co-administration of loteprednol at
time of surgery versus those not receiving loteprednol
(p = 0.29)
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of 15% (±SD 2.5%) in IOP. However, this
difference in percentage change between the
groups was not statistically significant
(p = 0.288). Percentage IOP decrease can be
seen in Fig. 3. Following matching, this
difference remained statistically insignificant
(-12.0 ± 1.5% vs -12.4 ± 3.0%).
DISCUSSION
Results of this retrospective study suggest that
there is no statistically significant difference in
the absolute or percentage decrease in IOP
between patients receiving and those not
receiving loteprednol after a 360 SLT
treatment. This was somewhat surprising given
that the postulated mechanism for SLT involves
an immunologic reaction that would be
expected to be altered by corticosteroid
administration. However, our findings are
consistent with previous studies that showed
no effect of corticosteroid use on ALT and SLT
[9, 14, 15]. The IOP-lowering effect of SLT in our
study was comparable to previous studies
examining laser as adjunctive therapy,
supporting our findings [17].
There are a number of limitations to this
study. The patients were under the care of two
glaucoma specialists at the Sabates Eye Centers
(KP and RK). There was a statistically significant
difference in baseline IOP between the two
groups (higher in the non-steroid group), which
could potentially affect both mean IOP post
treatment and percentage reduction in IOP. The
two groups were treated by different surgeons,
with differing philosophies regarding the effects
of corticosteroid administration on laser
trabeculoplasty. However, both surgeons were
experienced, performed 360 treatment, treat
patients from the same population, and have
similar practice patterns. The two groups of
patients were of similar age and there were no
statistically significant differences in the
number of glaucoma medications at any point.
The recommended approach for dealing with
unbalanced study designs where treatment is
not randomized or independent of baseline
patient characteristics is statistical matching
[19]. In this study, the difference in pre-
treatment IOP was eliminated following
nearest-neighbor matching, thus helping to
mitigate differences between physician
philosophies.









Kim et al. [15] ALT 27 Fluorometholone
(1 day before and
6 days after ALT)
4.6 ± 3.4 years
Realini et al. [16] SLT 50 Prednisolone acetate
(1 week after SLT)
3 months
Mcllraith et al. [17] SLT 74 Prednisolone acetate
versus ketorolac
1% (5 days after SLT)
1 year
ALT argon laser trabeculoplasty, SLT selective laser trabeculoplasty
118 Ophthalmol Ther (2013) 2:113–120
123
Another limitation was the variability in
follow-up due to the retrospective nature of
the study. As patients were seen at irregular
intervals following treatment over the course of
the year, a range of times was used for the
analysis. Despite this, some patients were still
not seen or lost to follow- up, decreasing the
number of time points available for analysis.
Finally, we did not attempt to effectively assess
post-operative inflammation or patient comfort
at any time point, although a previous study of
corticosteroids and SLT suggested no statistically
significant difference in either of these [16].
Taking these limitations into consideration,
we nevertheless believe that our study strongly
suggests that corticosteroids have minimal effect
on outcomes after SLT, which is supported by
previous studies on SLT and ALT (Table 3). One
advantage in our study is the larger sample size
(228 versus 50 eyes) and longer follow-up (1 year
versus 3 months compared to the only study
directly looking at concurrent corticosteroids
versus none with SLT [15–17]. The study by
Mcllraith et al. [17] was not designed to answer
the question of the effect of corticosteroids on
SLT outcome. As a result, post hoc power analysis
shows that with 60 eyes the study is expected to
detect a 3.2 mmHg corticosteroid effect with an
80% likelihood. Due to the study design, where
one eye was randomly chosen to receive
corticosteroid, the study by Realini et al. [16]
was powered to detect a 2.2 mmHg IOP
difference at 3 months. In comparison, our
study was powered to detect a 1.25 mmHg
difference at 1 year.
A randomized double-blinded study with a
higher power would be the best method to
definitively determine whether there is any
effect of corticosteroid use on the long-term
outcome of SLT. A simple calculation shows
that a randomized study would require more
than 450 eyes to detect a significant difference
of more than 1 mmHg change in IOP (a = 0.05,
b = 0.80). Until such data are available, we
recommend that individual clinical judgment
be used regarding whether to use topical
steroids in patients undergoing SLT.
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